ELAN vs. SMMT: Elanco Animal Health vs. Summit Therapeutics Stock Comparison

Company Profile

Elanco Animal Health (ELAN) and Summit Therapeutics (SMMT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ELAN is classified in Pharmaceuticals while SMMT is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Elanco Animal Health (ELAN) has a non-negative beta of 1.65.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Elanco Animal Health (ELAN) has no ROE value reported for this period; Summit Therapeutics (SMMT) reports a negative figure of -220.01%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

Both Elanco Animal Health (ELAN) at 6.64% and Summit Therapeutics (SMMT) at 0.00% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Elanco Animal Health (ELAN) reports revenue growth of 6.22%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: Elanco Animal Health (ELAN) reports EPS growth of -169.12%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Summit Therapeutics (SMMT) shows current ratio of 5.99 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.

Both Elanco Animal Health (ELAN) at 0.64 and Summit Therapeutics (SMMT) at 0.04 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Elanco Animal Health (ELAN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Elanco Animal Health (ELAN) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither Elanco Animal Health (ELAN) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

A sales-based read is only available for Elanco Animal Health (ELAN), whose P/S ratio of 2.50 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Elanco Animal Health (ELAN) at 1.95 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

Valuation Metrics